The Claim
Autologous mesenchymal stem cell therapy achieves a healing rate of 68.4% to 84.6% in complex anal fistulas among diabetic patients and demonstrates superior safety and operability compared to allogeneic mesenchymal stem cell products, which lack validated efficacy in this population.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In diabetic patients with complex anal fistulas, treatment using stem cells from the patient's own body results in healing rates between 68.4% and 84.6%, and is safer and easier to perform than stem cell treatments from donors, which have not been proven effective for this condition.
See the scientific wording
Autologous mesenchymal stem cell (MSC) therapy achieves a healing rate of 68.4% to 84.6% in complex anal fistulas among diabetic patients, with superior safety and operability compared to allogeneic MSC products, which lack validated efficacy in this population.
The body's own stem cells are injected into the infected wound, where they release chemicals that calm down the long-lasting inflammation, kill off harmful bacteria, and grow new blood vessels. This brings oxygen and healing materials to the damaged tissue, allowing the wound to close and heal.
What the research says
1 studyThe study says that using a diabetic patient’s own stem cells helps heal complex anal fistulas in about 70% to 85% of cases, and it’s safer than using stem cells from donors, which haven’t been proven to work well for diabetics. This matches exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.